BioSpace News Archive

Sage Therapeutics, Inc., a biopharmaceutical company leading the way to create a world with better brain health, announced that the Company will present at the following upcoming investor conferences in August:

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Monday, August 8, 2022, at 4:30 p.m. ET to report financial results for the second quarter ended June 30, 2022, and to provide a business update.

Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announced today that Jerome D. Jabbour, Chief Executive Officer of Matinas, has been invited to participate in a fireside chat at the BTIG Biotechnology Conference on Monday, August 8, 2022, at 2:00 p.m. ET.

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that the United States Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to evaluate KB407 in a clinical trial for cystic fibrosis.

Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, announced the closing of its previously announced business combination with Brookline Capital Acquisition Corp., a special purpose acquisition company.

Inspire Medical Systems, Inc., a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced the appointments of Cynthia Burks and Charisse Sparks, M.D., as independent directors to its Board, effective July 28, 2022.

MediWound Ltd., a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, announced that the Company will release its financial results for the second quarter ended June 30, 2022 on Tuesday, August 9, 2022.

Cullinan Oncology, Inc. today announced that its Chief Financial Officer, Jeff Trigilio, will participate in the following investor conferences in August.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce new interim data from 2nd line NSCLC patients (Part B) in the Phase II TACTI-002 trial.

CymaBay Therapeutics, Inc. today announced the completion of enrollment for RESPONSE, a global Phase 3 study evaluating seladelpar for patients with Primary Biliary Cholangitis (PBC).